Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
14 sep 2007 - 12:17
Statutaire naam
Crucell N.V.
Titel
Crucell to present pre-clinical results for H5N1 Virus treatment
Bericht
Leiden, The Netherlands, September 14, 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced that its researchers have discovered a monoclonal antibody that is active against H5N1 avian influenza. The studies will be presented at the 5th International Bird Flu Summit scheduled for September 27 and 28 in Las Vegas, Nevada.
Gerelateerde downloads
Datum laatste update: 24 december 2025